IgAN
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
Sitala BioSTL303
Fosun PharmaFXS6837 Dose 1
ADARx PharmaceuticalsADX-038 Dose Level 2
Clinical Trials (3)
Total enrollment: 120 patients across 3 trials
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Start: Jun 2026Est. completion: Sep 202715 patients
Phase 2Not Yet Recruiting
FXS6837 for the Treatment of IgAN Patients
Start: Mar 2026Est. completion: Nov 202760 patients
Phase 2Not Yet Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Start: Aug 2025Est. completion: Jun 202945 patients
Phase 2Recruiting
Related Jobs
Regional Account Manager, IgAN Nephrology, Indianapolis, IN
Indianapolis - IN; US - Lafayette - IN; US - Muncie - IN; US - Columbus - IN, US
1w ago
$99K - $237K/yr
Regional Account Manager, IgAN Nephrology, Atlanta North, GA
Atlanta - GA; US - Roswell - GA; US - Marietta - GA, US
1w ago
$104K - $249K/yr
Regional Account Manager, IgAN Nephrology, Cincinnati, OH
Cincinnati - OH; US - Middletown - OH; US - Dayton - OH, US
1w ago
$94K - $226K/yr
Regional Account Manager, IgAN Nephrology, Detroit, MI
Detroit - MI; US - Ann Arbor - MI; US - Dearborn - MI; US - Livonia - MI, US
1w ago
$94K - $226K/yr
Regional Account Manager, IgAN Nephrology, Atlanta South, GA
Atlanta - GA; US - Columbus - GA; US - Macon - GA, US
1w ago
$104K - $249K/yr
Regional Account Manager, IgAN Nephrology, Cleveland, OH
Cleveland - OH; US - Mentor - OH; US - Akron - OH, US
1w ago
$153K - $229K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 120 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.